Literature DB >> 30546894

Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.

Naoya Himuro1, Yumiko Niiya1, Takao Minakata1, Yutaka Oshima1, Daisuke Kataoka1, Shigeru Yamamoto1, Takashi Suzuki1, Mitsutaka Kadokura1.   

Abstract

The expression levels of thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), thymidylate synthase (TS) and orotate phosphoribosyltransferase (OPRT) may predict the clinical efficacy of 5-fluorouracil-based chemotherapy in patients with cancer. We herein investigated the differences in the mRNA levels of these enzymes in non-small-cell lung cancer (NSCLC) and evaluated their prognostic value for NSCLC treated by surgical resection. The intratumoral mRNA levels of TP, DPD, TS, and OPRT were quantified in 66 patients with pathological stage I and II NSCLC (adenocarcinoma or squamous cell carcinoma) following complete resection according to the Danenberg Tumor Profile method. The TP level was the only significant prognostic factor for disease-specific survival (DSS) following complete resection; the mean TP mRNA level differed significantly between the high and low mRNA expression groups. The DSS at 5 years was significantly higher in the low TP mRNA compared with that in the high TP mRNA expression group (83.4 vs. 58.6%, respectively; P=0.005). A Cox proportional hazards model revealed that pathological stage, sex, and TP expression were independent prognostic factors for DSS in patients with stage I and II NSCLC following complete resection. Thus, TP level may be used to monitor treatment efficacy and predict the outcome of NSCLC patients.

Entities:  

Keywords:  Danenberg tumor profile method; complete resection; non-small-cell lung cancer; prognostic factor; thymidine phosphorylase

Year:  2018        PMID: 30546894      PMCID: PMC6256090          DOI: 10.3892/mco.2018.1726

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  36 in total

1.  Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.

Authors:  Y Miyoshi; H Uemura; H Ishiguro; H Kitamura; N Nomura; P V Danenberg; Y Kubota
Journal:  Prostate Cancer Prostatic Dis       Date:  2005       Impact factor: 5.554

2.  Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer.

Authors:  H Amaya; N Tanigawa; C Lu; M Matsumura; T Shimomatsuya; T Horiuchi; R Muraoka
Journal:  Cancer Lett       Date:  1997-11-11       Impact factor: 8.679

3.  Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer.

Authors:  Yasushi Shintani; Mitsunori Ohta; Hirohisa Hirabayashi; Hisaichi Tanaka; Keiji Iuchi; Katsuhiro Nakagawa; Hajime Maeda; Tetsuo Kido; Shinichiro Miyoshi; Hikaru Matsuda
Journal:  Lung Cancer       Date:  2004-08       Impact factor: 5.705

4.  Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.

Authors:  H J Lenz; C G Leichman; K D Danenberg; P V Danenberg; S Groshen; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; Y Garcia; J Li; L Leichman
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

5.  Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma.

Authors:  Sung-Wei Lee; Tzu-Ju Chen; Li-Ching Lin; Chien-Feng Li; Li-Tzong Chen; Chung-Hsi Hsing; Han-Ping Hsu; Chia-Jung Tsai; Hsuan-Ying Huang; Yow-Ling Shiue
Journal:  Exp Mol Pathol       Date:  2013-05-28       Impact factor: 3.362

6.  Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.

Authors:  M I Koukourakis; A Giatromanolaki; K J O'Byrne; M Comley; R M Whitehouse; D C Talbot; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT.

Authors:  J Nakano; C Huang; D Liu; D Masuya; T Nakashima; H Yokomise; M Ueno; H Wada; M Fukushima
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

8.  Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.

Authors:  J Matsubara; T Nishina; Y Yamada; T Moriwaki; T Shimoda; T Kajiwara; T E Nakajima; K Kato; T Hamaguchi; Y Shimada; Y Okayama; T Oka; K Shirao
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

9.  Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.

Authors:  Tetsuro Tominaga; Tomoshi Tsuchiya; Koji Mochinaga; Junichi Arai; Naoya Yamasaki; Keitaro Matsumoto; Takuro Miyazaki; Toshiya Nagasaki; Atsushi Nanashima; Kazuhiro Tsukamoto; Takeshi Nagayasu
Journal:  BMC Cancer       Date:  2016-06-06       Impact factor: 4.430

10.  Thoracic and cardiovascular surgery in Japan during 2013: Annual report by The Japanese Association for Thoracic Surgery.

Authors:  Munetaka Masuda; Hiroyuki Kuwano; Meinoshin Okumura; Hirokuni Arai; Shunsuke Endo; Yuichiro Doki; Junjiro Kobayashi; Noboru Motomura; Hiroshi Nishida; Yoshikatsu Saiki; Fumihiro Tanaka; Kazuo Tanemoto; Yasushi Toh; Hiroyasu Yokomise
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.